Other Events ·
On July 6, 2026, Splash Beverage Group, Inc. entered into an Exclusive License Agreement with Argent Biopharma Limited…
SBEVWSplash Beverage Group, Inc.
On July 6, 2026, Splash Beverage Group, Inc. entered into an Exclusive License Agreement with Argent Biopharma Limited for worldwide rights to CannEpil®, a cannabinoid formulation for treating drug-resistant epilepsy and related neurological conditions. The company will pay a 15% royalty on net revenue for 10 years or until patent expiration. Development milestones include initiating Phase I trials within 24 months and Phase II within 48 months. As consideration, the company issued 5,500 shares of Series D Convertible Preferred Stock (stated value $5.5 million) to a noteholder to cancel $5.5 million in promissory notes. Additionally, C/M Capital Partners committed to invest at least $1 million within 60 days, with a $1 million sales bonus due upon reaching $5 million in cumulative net revenue. The company operates in the beverage and wellness industry, expanding into pharmaceutical cannabinoid products.